Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O0LQ
|
|||
| Former ID |
DCL000067
|
|||
| Drug Name |
BI 2536
|
|||
| Synonyms |
BI2536, BI 2536
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H39N7O3
|
|||
| Canonical SMILES |
CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
|
|||
| InChI |
1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
|
|||
| InChIKey |
XQVVPGYIWAGRNI-JOCHJYFZSA-N
|
|||
| CAS Number |
CAS 755038-02-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16456896, 23520952, 42443678, 47169965, 56374263, 79390480, 99436986, 103624610, 121279843, 123051122, 124757007, 125163812, 126581999, 126644897, 126671463, 126728164, 131480686, 134338770, 135263659, 135697720, 135727443, 136367307, 136368050, 136920290, 137134451, 137275913, 140810822, 143498076, 144115705, 152234950, 152258817, 152344043, 160647667, 162011967, 162037442, 162202556, 164789122, 165246686, 170494860, 172131314, 172659573, 172818898, 176223554, 177748502, 178102294, 180177875, 184826694, 186525083, 188899500, 198984127
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5666). | |||
| REF 2 | ClinicalTrials.gov (NCT00701766) BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia. U.S. National Institutes of Health. | |||
| REF 3 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. | |||
| REF 4 | BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007 Feb 20;17(4):316-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.